Immunogenicity testing and protein engineering

Formed in 2004, Antitope offer proprietary technologies as a comprehensive service for evaluating immunogenicity, identifying T cell epitopes, producing humanized antibodies and generating non-immunogenic proteins.

The core proprietary technologies include:

EpiScreen™ for accurately measuring the immunogenicity potential of therapeutic proteins and different formulations, identifying specific T cell epitopes or determining the potential of NCEs to induce late onset allergy like reactions.

Composite Human Antibodies™ to generate humanized, T cell epitope depleted antibodies for therapeutic use.

Composite Proteins™ to generate non-immunogenic proteins with desired biological function for therapeutic use.